Business Development

InnoCare is devoted to discovering, developing and commercializing novel treatments for oncology and autoimmune diseases. We have highly effective R&D and clinical teams with a proven track record.


Strong R&D team:

Our R&D team has brought 3 in-house discovered compounds to clinical stage drug candidates with 5 IND/CTA approvals.


Profound clinical development capabilities:

Our clinical development is highly efficient with a proven effectiveness. During the last two years, we have initiated 100 clinical trial sites and seven clinical trials, including two registrational trials, one / both of which have been submitted to the CDE. We completed both of Orelabrutinib’s CLL / SLL and MCL patient enrollment within one year, and NDA filing within two years of the first patient in.

To further our ability to provide patients with top-notch treatments, we are currently seeking strategy collaborations with biotech and pharmaceutical companies in the following areas:

Combination partnerships

Potential combination therapies that synergize with our current clinical assets.


Global or Ex-China rights of our current drug candidates that will enable us to maximize the commercial value of our pipeline globally.


Potential first-in-class or best-in-class drug candidates for development and commercialization China.

This website uses cookies and similar technologies, to enhance your browsing experience and provide personalized recommendations. By continuing to use this website, you agree to the use of cookies and similar technologies as described in our PRIVACY POLICY